Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 2:10 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2449–2472 of 54,995 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Patient Clear all

Conditions: Noise Exposure, Sedative Withdrawal Delirium, Sedative Toxicity
Interventions: Decibel Monitor; Other
Lead sponsor: Children's National Research Institute; Other
Eligibility: Up to 22 Years
Enrollment: 64 participants
Timeline: 2021
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Intraocular Inflammation, Suspected Endophthalmitis
Interventions: Non Applicable; Other
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 155,413 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Tarrytown, New York

Conditions: Multiple Myeloma, Refractory Multiple Myeloma
Interventions: Digital Health Coaching Program, Fitbit; Behavioral · Device
Lead sponsor: Pack Health; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Houston, Texas • Seattle, Washington

Conditions: Melanoma
Interventions: Cemiplimab, Lpilimumab, Fianlimab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Asthma
Interventions: Nebulized Budesonide, Usual care (albuterol with or without oral steroid); Drug
Lead sponsor: Deborah Gentile; Other
Eligibility: 1 Year to 8 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 2
States / cities: Bellevue, Pennsylvania • Pittsburgh, Pennsylvania

Conditions: Head and Neck Cancer, Oral Complications, Radiation Toxicity
Interventions: cevimeline hydrochloride; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 71
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 61 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Peers LEAD plus HLWD; Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 20 Years to 90 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Large B-cell Lymphoma
Interventions: R-1,3-Butanediol; Dietary Supplement
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cervical Cancer
Interventions: Pembrolizumab, Paclitaxel, Cisplatin, Carboplatin, Bevacizumab; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older · Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions: Binimetinib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Epilepsy
Interventions: USL261; Drug
Lead sponsor: UCB Biopharma S.P.R.L.; Industry
Eligibility: 12 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 31
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 28 more

Conditions: MYOPATHY
Interventions: Hematopoietic stem cell transplantation, Cyclophosphamide, Mesna, ATG(rabbit), Methylprednisolone, G-CSF, Rituxan; Biological · Drug
Lead sponsor: Northwestern University; Other
Eligibility: 16 Years to 65 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2016
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Anterior Cruciate Ligament Rupture, Anterior Cruciate Ligament Tear, Anterior Cruciate Ligament Injuries
Interventions: Self-guided pre-habilitation exercise program, Traditional pre-habilitation; Other
Lead sponsor: WellSpan Health; Other
Eligibility: 13 Years to 50 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: York, Pennsylvania

Conditions: Neuroendocrine Tumors
Interventions: LUTATHERA; Drug
Lead sponsor: Advanced Accelerator Applications; Industry
Eligibility: 18 Years and older
Enrollment: 1,014 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 4
States / cities: Phoenix, Arizona • Portland, Ohio • Portland, Oregon + 1 more

Conditions: Healthy, Muscular Dystrophy, Retinal Degeneration, Skin Diseases, Virus Diseases
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Healthy volunteers: Accepts healthy volunteers
Timeline: 1978 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Liver Disease, Fatty Liver
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy
Interventions: Not listed
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 14 Years to 19 Years
Enrollment: 1,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Rheumatoid Arthritis
Interventions: MRC375, Matching Placebo, MRC375 150mg; Drug
Lead sponsor: Molecular Research Center, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 19
States / cities: Mobile, Alabama • Long Beach, California • Los Alamitos, California + 16 more

Conditions: Atrial Fibrillation, Heart Failure
Interventions: Ranolazine, Placebo; Drug
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Murray, Utah

Conditions: Chronic Lymphocytic Leukemia
Interventions: Ofatumumab; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 6
States / cities: Denver, Colorado • Fort Myers, Florida • St. Petersburg, Florida + 3 more

Conditions: Prostate Cancer
Interventions: abiraterone acetate, Prednisone; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2024
U.S. locations: 205
States / cities: Jonesboro, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 148 more

Conditions: Metastatic Colorectal Carcinoma, Recurrent Colorectal Carcinoma, Refractory Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
Interventions: Atezolizumab, Bevacizumab, Capecitabine, Laboratory Biomarker Analysis, Placebo; Drug · Biological · Other
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 18 Years and older
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 10
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 7 more

Conditions: Pressure Ulcer
Interventions: Envision® Patient Support System; Device
Lead sponsor: Hill-Rom; Industry
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cataract, Multifocal Intraocular Lens
Interventions: Clareon PanOptix Pro and Clareon Vivity Intraocular Lens, Clareon PanOptix Pro Intraocular Lenses; Device
Lead sponsor: Brian Shafer; Other
Eligibility: 18 Years and older
Enrollment: 346 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 5
States / cities: Baltimore, Maryland • Alexandria, Minnesota • Bozeman, Montana + 2 more

Search by objective public record fields.

Sound Levels in the Pediatric Cardiac Critical Care Unit and Their Correlation With Sedation Administration, Delirium Scores and Patient Heart Rate

A Study of the Incidence of Intraocular Inflammation and Suspected Endophthalmitis Among Patients Treated With Aflibercept, Vial and Pre-filled Syringe, 2014-2022

Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma with Isatuximab

PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma

Effect of Nebulized Budesonide and Oral Corticosteroids on Wheezing Episode Relapse in Children

Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer

Peers LEAD Plus Healthy Living With Diabetes (HLWD)

BHB & CAR-T for Lymphomas

Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer

Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)

Study to Evaluate the Long-term Safety and Tolerability of USL261 in Patients With Seizure Clusters

Stem Cell Transplantation in Idiopathic Inflammatory Myopathy Diseases

Quantifying the Benefits of Supervised vs. Unsupervised Pre-habilitation for Patients With Acute ACL Tears

Post-Authorization Long-Term Safety Study of LUTATHERA

Studies of Patients With Skin Disease, Patients With Neurological Degenerations, and Normal Volunteers

Dynamic Post-Prandial Metabolism in Patients With Non-Alcoholic Fatty Liver Disease

Adolescents' Use of Complementary and Alternative Medicine

A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients

The Use of Ranolazine for Atrial Fibrillation and Diastolic Heart Failure

Rapid Infusion of Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia

S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy

Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer

Envision® Surface Evaluation

Visual Outcomes in Patients Contralaterally Implanted With PanOptix Pro and Clareon Vivity Compared to Bilateral Implantation of PanOptix Pro